Open AccessIncreased EHD 1 in non‐small cell lung cancer predicts poor survival
Author(s) -
Lu Hailing,
Meng Qingwei,
Wen Yuan,
Hu Jing,
Zhao Yanbin,
Cai Li
Publication year - 2013
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.12043
Subject(s) - medicine , lung cancer , epidermal growth factor receptor , oncology , immunohistochemistry , hazard ratio , proportional hazards model , adjuvant , cancer , confidence interval
Background One of the main challenges of lung cancer research is identifying patients at high risk for recurrence after surgical resection. We evaluated the prognostic power of four proteins in the endocytic pathway in 114 non‐small cell lung cancer patients ( NSCLC ). Methods We tested the four proteins (epidermal growth factor receptor [ EGFR ], RAB11FIP3 , EHD 1, and caveolin‐1), critical nodes in the endocytosis/recycling pathway, by immunohistochemistry in paraffin sections from 114 non‐small cell lung cancer patients. We analyzed the correlation between our target proteins and clinical variables. Within these variables, an overall survival ( OS ) prediction model was constructed using C ox proportional hazard regression. Results EHD 1 expression correlated with gender (P = 0.001), histology type (P < 0.001), and EGFR expression (P = 0.008), but not with any of the other clinical parameters. Statistical correlation analysis showed that the expression of EHD 1 positively correlated with high level of EGFR (P < 0.001) and RAB11FIP3 (P < 0.001), and the expression of caveolin‐1 positively correlated with high level of EGFR (P < 0.001) in the NSCLC samples. EHD 1 expression was an OS prognostic factor for all of the patients (P = 0.009), for the group of adjuvant chemotherapy‐treated patients (P = 0.006), and for the EGFR positive patients (P = 0.034). Conclusions We identified EHD 1 as a strong prognostic predictive factor in NSCLC . The expression level of EHD 1 would potentially be useful in developing customized strategies for managing lung cancer, such as the selection of patients eligible for chemotherapy.